AllianceBernstein’s Protalix BioTherapeutics PLX Stock Holding History

AllianceBernstein’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$52.4K	Buy	24,160 +12,440	+106%	+$26.3K	﹤0.01%	3292
2026 Q1	$21.1K	Hold	11,720	–	–	﹤0.01%	3220
2025 Q4	$21.1K	Hold	11,720	–	–	﹤0.01%	3229
2025 Q3	$26K	Hold	11,720	–	–	﹤0.01%	3233
2025 Q2	$17.3K	Buy	+11,720	New	+$24K	﹤0.01%	3231
2024 Q2	–	Sell	-23,400	Closed	-$29.5K	–	3284
2024 Q1	$29.5K	Hold	23,400	–	–	﹤0.01%	3113
2023 Q4	$41.7K	Hold	23,400	–	–	﹤0.01%	3143
2023 Q3	$38.8K	Hold	23,400	–	–	﹤0.01%	3152
2023 Q2	$46.8K	Buy	+23,400	New	+$55.7K	﹤0.01%	3135
2014 Q2	–	Sell	-9	Closed	–	–	3590
2014 Q1	$0	Hold	9	–	–	﹤0.01%	3667
2013 Q4	$0	Hold	9	–	–	﹤0.01%	3472
2013 Q3	$0	Buy	+9	New	+$462	﹤0.01%	3492

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

AllianceBernstein's PLX Position: Q2 2026 in Review

AllianceBernstein increased its Protalix BioTherapeutics (PLX) stake by 106% in Q2 2026, buying an estimated $26.3K and bringing the position to 24,160 shares worth $52.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3292.

AllianceBernstein first reported a position in PLX in Q3 2013 and has held it in 12 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

AllianceBernstein held 24,160 shares of Protalix BioTherapeutics worth $52.4K as of Q2 2026.
AllianceBernstein bought 12,440 Protalix BioTherapeutics shares in Q2 2026, an estimated $26.3K.
Protalix BioTherapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #3292 holding.
AllianceBernstein first reported a position in Protalix BioTherapeutics in Q3 2013 and has held it in 12 quarters since.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.